程序性细胞死亡配体 1 在外周血中的浓度是一种用于诊断食管鳞癌的有用的生物标志物。
The concentration of programmed cell death-ligand 1 in the peripheral blood is a useful biomarker for esophageal squamous cell carcinoma.
机构信息
Department of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.
Miwa Central Clinic, 1-336-6 Miwa, Mito, Ibaraki, 310-0911, Japan.
出版信息
Esophagus. 2018 Apr;15(2):103-108. doi: 10.1007/s10388-018-0604-1. Epub 2018 Feb 7.
BACKGROUND
We determined the serum concentrations of Programmed cell death-1 (PD-1) and its ligands (PD-L1 and PD-L2) in patients with esophageal squamous cell carcinoma (ESCC).
METHODS
Blood samples were collected from 85 patients with histologically proved ESCC. Serum levels of PD-1, PD-L1, and PD-L2 were measured using enzyme linked immunosorbent assays. Correlations between serum PD-1, PD-L1, and PD-L2 concentration and tumor depth, number of lymph node metastases, organ metastasis status, or disease stage were assessed and five-year survival rates according to clinicopathological characteristics were calculated.
RESULTS
The concentration of PD-1 was not differed according to tumor progression. On the other hand, the average concentration of PD-L1 in patients with T3/T4 disease was 15.6 (12.2-18.3) pg/mL (25-75%), and this was significantly higher than that in patients with Tis/T1/T2 disease (p = 0.020). Similarly, PD-L1 levels were significantly higher in patients with positive lymph nodes than in cases with negative lymph node involvement (p = 0.006) and were higher in patients with organ metastasis (p = 0.123) and in more advanced stage (p = 0.006). Similar tendency was observed regarding PD-L2 concentrations. PD-L2 concentration was higher in T3, T4 cases (p = 0.008), in LN positive cases (p = 0.032), and in more advanced stage (p = 0.024).
CONCLUSION
Our data showed that a concentration of PD-L1 in peripheral blood was high in advanced cancer and high concentration of PD-L1 predicted disease progression and also poor survival in patients with ESCC.
背景
我们测定了食管鳞癌（ESCC）患者血清中程序性死亡受体 1（PD-1）及其配体（PD-L1 和 PD-L2）的浓度。
方法
收集 85 例经组织学证实的 ESCC 患者的血样。采用酶联免疫吸附试验（ELISA）检测血清 PD-1、PD-L1 和 PD-L2 水平。评估血清 PD-1、PD-L1 和 PD-L2 浓度与肿瘤深度、淋巴结转移数量、器官转移状态或疾病分期的相关性，并根据临床病理特征计算 5 年生存率。
结果
PD-1 浓度与肿瘤进展无关。另一方面，T3/T4 期患者 PD-L1 的平均浓度为 15.6（12.2-18.3）pg/ml（25-75%），显著高于Tis/T1/T2 期患者（p=0.020）。同样，淋巴结阳性患者的 PD-L1 水平显著高于淋巴结阴性患者（p=0.006），且有器官转移患者的 PD-L1 水平较高（p=0.123），且疾病分期较高（p=0.006）。PD-L2 浓度也有类似的趋势。T3、T4 期患者的 PD-L2 浓度较高（p=0.008），淋巴结阳性患者的 PD-L2 浓度较高（p=0.032），且疾病分期较高（p=0.024）。
结论
我们的数据表明，外周血中 PD-L1 的浓度在晚期癌症中较高，高浓度的 PD-L1 预测 ESCC 患者的疾病进展和不良预后。
Zotero 插件